The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study
European Addiction Research · 2024 · 30 (1) · 1-13
DOI: 10.1159/000535016 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Addiction Research, online erschienen am 29.11.2023. Verfasst von Christoffer Brynte und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Counc…. Hauptthemen laut MEDLINE: Methylphenidate, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Substance-Related Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Attention deficit/hyperactivity disorder (ADHD) with co-occurring substance use disorder (SUD) is associated with poor treatment outcomes. Two randomized controlled trials, utilizing robust doses of stimulants, demonstrated a significant effect on treatment outcomes in patients with ADHD/SUD. This study aimed to investigate differences in executive functioning and explore the dose-dependent effect of OROS-methylphenidate (MPH) in patients with comorbid ADHD and amphetamine use disorder (ADHD+AMPH) and patients with ADHD only.
Methods
Three groups (ADHD+AMPH, ADHD only, and healthy controls) were assessed repeatedly with a neuropsychological test battery. An exploratory within-subject single-blinded design was employed where the ADHD only group received a maximum dose of 72 mg OROS-MPH, the ADHD+AMPH group a maximum dose of 180 mg, whereas the healthy subjects did not receive any study medication. Both ADHD groups received the same dose titration up to 72 mg OROS-MPH.
Results
The ADHD+AMPH group demonstrated a significantly poorer motor inhibition and spatial working memory and reported more severe ADHD symptoms compared to the ADHD only group. 180 mg OROS-MPH was associated with a significant improvement in executive functioning in the dual diagnosis group. However, the exploratory study design and recruitment issues do not allow for any conclusion to be drawn regarding the effect of 180 mg OROS-MPH.
Conclusion
Patients with ADHD+AMPH present with more severe neurocognitive deficits compared to ADHD only. The effect of 180 mg OROS-MPH on cognition in patients with ADHD+AMPH was inconclusive. Future studies should consider recruitment issues and high drop-out rates in this study population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.
- Department of Psychiatry, Columbia University Irving Medical Center/New York State Psychiatric Institute, New York, New York, USA.
Zitieren
APA
Brynte, C., Konstenius, M., Khemiri, L., Bäcker, A., Guterstam, J., Levin, F. R., Jayaram-Lindström, N., & Franck, J. (2024). The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study. European Addiction Research, 30(1), 1-13. https://doi.org/10.1159/000535016
Vancouver
Brynte C, Konstenius M, Khemiri L, Bäcker A, Guterstam J, Levin FR, et al. The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study. European Addiction Research. 2024;30(1):1-13. doi:10.1159/000535016
BibTeX
@article{Brynte2024,
author = {Brynte, Christoffer and Konstenius, Maija and Khemiri, Lotfi and Bäcker, Amanda and Guterstam, Joar and Levin, Frances R and Jayaram-Lindström, Nitya and Franck, Johan},
title = {The Effect of Methylphenidate on Cognition in Patients with Comorbid Attention Deficit/Hyperactivity Disorder and Amphetamine Use Disorder: An Exploratory Single-Blinded within-Subject Study},
journal = {European Addiction Research},
year = {2024},
volume = {30},
number = {1},
pages = {1--13},
doi = {10.1159/000535016}
}
EUVIMED